Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 218-491-7 | CAS number: 2163-00-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics
- Type of information:
- other: Expert statement
- Adequacy of study:
- key study
- Study period:
- 2013-01-16
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Expert statement, no study available
Data source
Reference
- Reference Type:
- other: Expert statement
- Title:
- Unnamed
- Year:
- 2 013
- Report date:
- 2013
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Guideline:
- other: Expert statement
- Principles of method if other than guideline:
- Expert statement
- GLP compliance:
- yes
Test material
- Reference substance name:
- 1,6-dichlorohexane
- EC Number:
- 218-491-7
- EC Name:
- 1,6-dichlorohexane
- Cas Number:
- 2163-00-0
- Molecular formula:
- C6H12Cl2
- IUPAC Name:
- 1,6-dichlorohexane
- Test material form:
- other: Colourless liquid
Constituent 1
Test animals
- Details on test animals or test system and environmental conditions:
- not applicable
Administration / exposure
- Details on exposure:
- not applicable
- Duration and frequency of treatment / exposure:
- not applicable
Doses / concentrations
- Remarks:
- Doses / Concentrations:
not applicable
- No. of animals per sex per dose / concentration:
- not applicable
- Positive control reference chemical:
- not applicable
- Details on study design:
- not applicable
- Details on dosing and sampling:
- not applicable
- Statistics:
- not applicable
Results and discussion
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Generally, oral absorption is favoured for molecular weights below 500 g/mol. This characteristic combined with the moderate lipophilic log Pow value and water solubility allow dissolution of 1,6-dichlorohexane in the gastro-intestinal fluids and contact with the mucosal surface.
Administered in traganth in an acute oral toxicity study performed on rats, 1,6-dichlorohexane lead to a LD50 of 2675 mg/kg bw. Furthermore, long-term administration of 1,6-dichlorohexane in a reproduction/developmental toxicity screening study indicate that the compound became bioavailable. Following oral administration hydrolysis of 1,6-dichlorohexane cannot be excluded under the acidic milieu of the stomach and the slightly basic milieu of the intestine. Potential hydrolysis products are chlorohexanol and 1,6-hexanediol.
Based on the vapour pressure of approximately 11 Pa 1,6-dichlorohexane might become available for inhalation. If the substance would reach the lungs in its vapour or gaseous state, absorption directly across the respiratory tract epithelium by passive diffusion is likely to occur due to its moderate log Pow value and water solubility. In an acute inhalation toxicity study rats were exposed to a saturated vapour atmosphere of 1,6-dichlorohexane. As no mortality and no specific effects of systemic toxicity were observed these results indicate that systemic availability after inhalation might be low.
Similarly, based on physico–chemical properties of 1,6-dichlorohexane dermal penetration is estimated to be low to moderate. Due to lipophilicity of the substance uptake into the stratum corneum is estimated to be high. However, low water solubility of 1,6-dichlorohexane limit the partition from stratum corneum into the epidermis. These assumptions based on the physicochemical properties of 1,6-dichlorohexane are further supported by the results achieved from
an acute dermal toxicity study performed on rabbits. During this study no test item related mortality and no specific effects of systemic toxicity were observed. The LD50 was >2000 mg/kg bw. However, 1,6-dichlorohexane caused skin irritation, which in turn may favour direct absorption into the systemic circulation.
Taken together, physico-chemical properties and experimental data indicate bioavailability of 1,6-dichlorohexane via oral route and, to a less extend via dermal and inhalation route. - Details on distribution in tissues:
- Assuming that 1,6-dichlorohexane is absorbed into the body following oral intake to some extend, it may be distributed into the interior part of cells due to its moderate lipophilic properties and in turn the intracellular concentration may be higher than extracellular concentration particularly in adipose tissues. No target organ was identified and no embryotoxicity/teratogenicity was observed in the reproduction and developmental performance. However, penetration through the placenta could not entirely be excluded. Reduced body weight and postnatal mortality of the offspring observed during lactation is estimated to be a consequence of maternal systemic toxicity. Based on their BCF values both, the parent molecule 1,6-dichlorohexane and its possible hydrolysis products have no potential to bioaccumulate in the human body.
- Details on excretion:
- As discussed above, 1,6-dichlorohexane may be hydrolysed and/or metabolised and will probably not be excreted in its original form. Dependent on the molecular weight of the metabolism products renal or biliary excretion is favoured. Generally, characteristics favourable for urinary excretion are low molecular weights (~300 g/mol), good water solubility and ionization of the molecule at the pH of the urine, which is applicable for the conjugated metabolites (glucuronides and sulphates). Renal excretion was also shown for metabolites of adipic acid (urea, glutamic acid, lactic acid among others, Rusoff, I.I. et al., 1960). On the
other hand, metabolites with a higher molecular weight, like glutathione adducts, are expected to be active secreted in the bile and excreted in the faeces.
Metabolite characterisation studies
- Details on metabolites:
- The chlorine atoms of 1,6-dichlorohexane are estimated to be substituted by glutathione abiotically as well as enzymatically. 1,6-dichlorohexane might further be hydrolysed slowly after being in contact with an aqueous solution as well as enzymatically. The first potential degradation product, chlorohexanol is estimated to be converted abiotically or by glutathione transferase into hexanol glutathione, which might be degraded to mercapturic acid in order to ultimately facilitate excretion. Furthermore, O-conjugation with glucuronic acid or sulphate is expected to occur which is in turn applicable for 1,6-hexanediol, the
second potential hydrolysis product. Oxidation of 1,6-hexanediol by ADH and AlDH is an alternative metabolic pathway resulting in adipic acid, which in turn will enter the β-oxidation pathway (Rusoff, I.I. et al., 1960). There is no indication for metabolic activation as no induction of mutation as well as chromosomal aberration was observed in the in vitro genotoxicity assays in the presence of a metabolic activation system.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): no bioaccumulation potential based on study results
Based on physico-chemical characteristics, particularly water solubility and octanol-water partition coefficient absorption via oral route and to a less extend via dermal and inhalation route is likely to occur. Intracellular concentration is likely to be higher than extracellular due to the moderate lipophilicity of 1,6-dichlorohexane. Hydrolytic and metabolic conversion into chlorohexanol and 1,6-hexandiol might occur and conjugation of Phase I-metabolites may further increase hydrophilicity. Excretion via urine is assumed to be the main excretion pathway of potential metabolites formed due to their molecular weight. However, biliary excretion could not be excluded for glutathione adducts of 1,6-dichlorohexane. Bioaccumulation of 1,6- dichlorohexane itself and its potential metabolites is not likely to occur based on their physico-chemical properties.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.